Announcement of TTY Biopharm's unaudited income information in December 2023
2024.1.17
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2024/01/17 | Time of announcement | 13:38:40 |
| Subject | Announcement of TTY Biopharm's unaudited income information in December 2023 | ||||
| Date of events | 2024/01/17 | To which item it meets | paragraph 53 | ||
| Statement | 1.Date of occurrence of the event:2024/01/17 2.Company name:TTY Biopharm Co., Ltd. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:N/A 5.Cause of occurrence:TTY Biopharm posted a consolidated net sales of $482,877 thousands (expressed in NT dollars; unaudited), a consolidated operating profit of $58,044 thousands, and a consolidated loss before tax of $15,822 thousands in December 2023; net loss attributed to stockholders of the company was $5,333 thousands; EPS is $(0.02). Year-to-date consolidated net sales was $5,480,317 thousands (in NT dollars unaudited), a consolidated operating profit was $1,354,788 thousands and consolidated income before tax was $1,392,019 thousands until December 2023; year-to-date net income attributed to stockholders of the company was $1,082,325 thousands; EPS is $4.35. 6.Countermeasures:None. 7.Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): The numbers above are unaudited. In term of the final net sales and profits, quarterly financial reports audited by independent accountants will prevail. |
||||